QualityStocks would like to highlight Provectus Pharmaceuticals (OTCBB: PVCT). The company specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer, and cancers of the liver.
In the company’s news yesterday, Provectus Pharmaceuticals Inc., announced it has received guidance from the U.S. Food and Drug Administration (FDA) to submit its phase 3 protocol for review.
This guidance is in response to Provectus’ request for a final end-of-phase 2 meeting regarding consensus of the design of a planned pivotal phase 3 randomized controlled trial (RCT) of PV-10 for metastatic melanoma. In its response, Provectus said the FDA indicated that an additional end-of-phase 2 meeting with Provectus is not required.
Receiving Special Protocol Assessment (SPA) for approval of PV-10 for melanoma indication would represent an agreement from the FDA that the company’s phase 3 study design endpoints, statistical analyses, and other components of the planned clinical trials are acceptable to support approval of the product.
“Following our third meeting with the Agency in October, we believed that significant progress had been achieved in defining the threshold the FDA will require for approval in melanoma, which is a rapidly evolving therapeutic area,” Craig Dees, Ph.D., CEO of Provectus stated in the press release. “Using recommendations of senior FDA officials from that meeting, including those related to patient population and primary endpoint, we intend to request SPA review of our protocol, which we expect will be submitted before the end of the first quarter. While SPA can occur over as little as 45 calendar days, it is important to note that this is frequently an iterative process, and could take longer as we work with the Agency to reach ultimate agreement on study design.”
About QualityStocks:
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit
http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit
http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
